AC-178,335, Antagonist of SST 2 receptor;Antagonist of SST 5 receptor, CAS No.212966-15-9, Antagonist of SST 2 receptor;Antagonist of SST 5 receptor

CAS: 212966-15-9 Cat. No.: rp173361 PubChem CID: 9832890

GRADE & PURITY Moligand™

Specifications

Product Name

AC-178,335, Antagonist of SST 2 receptor;Antagonist of SST 5 receptor, CAS No.212966-15-9

Sinonimi

AC 178335

Grado

Moligand™

Specifiche e purezza

Moligand™

Tipo di azione

ANTAGONIST

Meccanismo d'azione

Antagonist of SST 2 receptor;Antagonist of SST 5 receptor

CAS

212966-15-9

Tipo di molecola

Peptidi

Product Line

Prodotti biologici

Stoccaggio e spedizione

Condizioni di conservazione di stoccaggio

Room temperature

Obiettivi associati (umani)

SSTR2 Tclin Somatostatin receptor type 2 (0 Activities)

Discover Target: SSTR2

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

SSTR5 Tclin Somatostatin receptor type 5 (0 Activities)

Discover Target: SSTR5

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

Informazioni genetiche

• Alternate Names: AC 178335
• Reference:
  • 1. Kinetics and inhibition of recombinant human cystathionine gamma-lyase. Toward the rational control of transsulfuration., The Journal of biological chemistry, Steegborn, C C and 7 more authors.
  • 2. Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences., Proceedings of the National Academy of Sciences of the United States of America, Strausberg, Robert L RL and 83 more authors.
  • 3. Genomic basis of cystathioninuria (MIM 219500) revealed by multiple mutations in cystathionine gamma-lyase (CTH)., Human genetics, Wang, Jian J and Hegele, Robert A RA.
  • 4. Cloning and nucleotide sequence of human liver cDNA encoding for cystathionine gamma-lyase., Biochemical and biophysical research communications, Lu, Y Y, O'Dowd, B F BF, Orrego, H H and Israel, Y Y.
  • 5. Single nucleotide polymorphism in CTH associated with variation in plasma homocysteine concentration., Clinical genetics, Wang, J J, Huff, A M AM, Spence, J D JD and Hegele, R A RA.
  • 6. Cystathionine gamma-lyase overexpression inhibits cell proliferation via a H2S-dependent modulation of ERK1/2 phosphorylation and p21Cip/WAK-1., The Journal of biological chemistry, Yang, Guangdong G, Cao, Kun K, Wu, Lingyun L and Wang, Rui R.
  • 7. The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)., Genome research, Gerhard, Daniela S DS and 115 more authors.
  • 8. Towards a proteome-scale map of the human protein-protein interaction network., Nature, Rual, Jean-François JF and 37 more authors.
  • 9. The DNA sequence and biological annotation of human chromosome 1., Nature, Gregory, S G SG and 178 more authors.
  • 10. Polymorphisms in one-carbon metabolism and trans-sulfuration pathway genes and susceptibility to bladder cancer., International journal of cancer, Moore, Lee E LE and 14 more authors. more
  • 11. Toward a confocal subcellular atlas of the human proteome., Molecular & cellular proteomics : MCP, Barbe, Laurent L and 10 more authors.
  • 12. Kinetic properties of polymorphic variants and pathogenic mutants in human cystathionine gamma-lyase., Biochemistry, Zhu, Weidong W, Lin, Alexander A and Banerjee, Ruma R.
  • 13. Pathway-based evaluation of 380 candidate genes and lung cancer susceptibility suggests the importance of the cell cycle pathway., Carcinogenesis, Hosgood, H Dean HD and 12 more authors.
  • 14. Relationship between cystathionine gamma-lyase gene polymorphism and essential hypertension in Northern Chinese Han population., Chinese medical journal, Li, Yun Y and 8 more authors.
  • 15. Active cystathionine beta-synthase can be expressed in heme-free systems in the presence of metal-substituted porphyrins or a chemical chaperone., The Journal of biological chemistry, Majtan, Tomas T, Singh, Laishram R LR, Wang, Liqun L, Kruger, Warren D WD and Kraus, Jan P JP.
  • 16. MALDI-TOF MS genotyping of polymorphisms related to 1-carbon metabolism using common and mass-modified terminators., Clinical chemistry, Meyer, Klaus K, Fredriksen, Ase A and Ueland, Per Magne PM.
  • 17. Structural basis for the inhibition mechanism of human cystathionine gamma-lyase, an enzyme responsible for the production of H(2)S., The Journal of biological chemistry, Sun, Qingxiang Q and 10 more authors.
  • 18. Oral facial clefts and gene polymorphisms in metabolism of folate/one-carbon and vitamin A: a pathway-wide association study., Genetic epidemiology, Boyles, Abee L AL and 16 more authors.
  • 19. Large-scale proteomics and phosphoproteomics of urinary exosomes., Journal of the American Society of Nephrology : JASN, Gonzales, Patricia A PA and 7 more authors.
  • 20. An association study of 45 folate-related genes in spina bifida: Involvement of cubilin (CUBN) and tRNA aspartic acid methyltransferase 1 (TRDMT1)., Birth defects research. Part A, Clinical and molecular teratology, Franke, Barbara B and 7 more authors.
  • 21. Polymorphisms in innate immunity genes and lung cancer risk in Xuanwei, China., Environmental and molecular mutagenesis, Shen, Min M and 12 more authors.
  • 22. H2S biogenesis by human cystathionine gamma-lyase leads to the novel sulfur metabolites lanthionine and homolanthionine and is responsive to the grade of hyperhomocysteinemia., The Journal of biological chemistry, Chiku, Taurai T and 5 more authors.
  • 23. Variations in folate pathway genes are associated with unexplained female infertility., Fertility and sterility, Altmäe, Signe S and 7 more authors.
  • 24. Bile-acid-activated farnesoid X receptor regulates hydrogen sulfide production and hepatic microcirculation., World journal of gastroenterology, Renga, Barbara B, Mencarelli, Andrea A, Migliorati, Marco M, Distrutti, Eleonora E and Fiorucci, Stefano S.
  • 25. Cystathionine gamma-lyase: Clinical, metabolic, genetic, and structural studies., Molecular genetics and metabolism, Kraus, Jan P JP and 14 more authors.
  • 26. Relative contributions of cystathionine beta-synthase and gamma-cystathionase to H2S biogenesis via alternative trans-sulfuration reactions., The Journal of biological chemistry, Singh, Sangita S, Padovani, Dominique D, Leslie, Rachel A RA, Chiku, Taurai T and Banerjee, Ruma R.
  • 27. PTEN identified as important risk factor of chronic obstructive pulmonary disease., Respiratory medicine, Hosgood, H Dean HD, Menashe, Idan I, He, Xingzhou X, Chanock, Stephen S and Lan, Qing Q.
  • 28. Genetic susceptibility to distinct bladder cancer subphenotypes., European urology, Guey, Lin T LT and 18 more authors.
  • 29. Gene-centric association signals for lipids and apolipoproteins identified via the HumanCVD BeadChip., American journal of human genetics, Talmud, Philippa J PJ and 38 more authors.
  • 30. Integrative predictive model of coronary artery calcification in atherosclerosis., Circulation, McGeachie, Michael M and 13 more authors.
  • 31. Cystathionine beta-synthase 844Ins68 polymorphism is not associated with the levels of homocysteine and cysteine in an Indian population., Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals, Kumar, Jitender J, Garg, Gaurav G, Karthikeyan, Ganesan G and Sengupta, Shantanu S.
  • 32. The expression and activity of cystathionine-γ-lyase and 3-mercaptopyruvate sulfurtransferase in human neoplastic cell lines., Amino acids, Jurkowska, Halina H, Placha, Wojciech W, Nagahara, Noriuki N and Wróbel, Maria M.
  • 33. Ancient origin of the CTH alelle carrying the c.200C>T (p.T67I) variant in patients with cystathioninuria., Clinical genetics, Espinós, C C and 8 more authors.
  • 34. Variation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study., Diabetes care, Bailey, Swneke D SD and 11 more authors.
  • 35. Maternal genes and facial clefts in offspring: a comprehensive search for genetic associations in two population-based cleft studies from Scandinavia., PloS one, Jugessur, Astanand A and 12 more authors.
  • 36. [Expression of cystathionine-γ-lyase/hydrogen sulfide pathway in CVB3-induced myocarditis in mice]., Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics, Hua, Wang W and 6 more authors.
  • 37. Folate-metabolizing gene variants and pregnancy outcome of IVF., Reproductive biomedicine online, Laanpere, M M and 5 more authors.
  • 38. Specificity protein-1 as a critical regulator of human cystathionine gamma-lyase in smooth muscle cells., The Journal of biological chemistry, Yang, Guangdong G, Pei, Yanxi Y, Teng, Huajian H, Cao, Qiuhui Q and Wang, Rui R.
  • 39. Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium., Briefings in bioinformatics, Gaudet, Pascale P, Livstone, Michael S MS, Lewis, Suzanna E SE and Thomas, Paul D PD.
  • 40. Expression of cystathionine β-synthase and cystathionine γ-lyase in human pregnant myometrium and their roles in the control of uterine contractility., PloS one, You, Xing-Ji XJ and 8 more authors.
  • 41. MicroRNA-21 represses human cystathionine gamma-lyase expression by targeting at specificity protein-1 in smooth muscle cells., Journal of cellular physiology, Yang, Guangdong G, Pei, Yanxi Y, Cao, Qiuhui Q and Wang, Rui R.
  • 42. H2S-Induced sulfhydration of the phosphatase PTP1B and its role in the endoplasmic reticulum stress response., Science signaling, Krishnan, Navasona N, Fu, Cexiong C, Pappin, Darryl J DJ and Tonks, Nicholas K NK.
  • 43. Characterization of hydrogen sulfide and its synthases, cystathionine β-synthase and cystathionine γ-lyase, in human prostatic tissue and cells., Urology, Guo, Hui H and 5 more authors.
  • 44. Sp1 is involved in regulation of cystathionine γ-lyase gene expression and biological function by PI3K/Akt pathway in human hepatocellular carcinoma cell lines., Cellular signalling, Yin, Peng P and 12 more authors.
  • 45. H₂S protects against pressure overload-induced heart failure via upregulation of endothelial nitric oxide synthase., Circulation, Kondo, Kazuhisa K and 14 more authors.
  • 46. Reduced cystathionine γ-lyase and increased miR-21 expression are associated with increased vascular resistance in growth-restricted pregnancies: hydrogen sulfide as a placental vasodilator., The American journal of pathology, Cindrova-Davies, Tereza T and 5 more authors.
  • 47. Dysregulation of hydrogen sulfide producing enzyme cystathionine γ-lyase contributes to maternal hypertension and placental abnormalities in preeclampsia., Circulation, Wang, Keqing K and 14 more authors.
  • 48. Regulation of cystathionine γ-lyase in mammalian cells by hypoxia., Biochemical genetics, Wang, Maoxian M, Guo, Zhanyun Z and Wang, Shilong S.
  • 49. A genome-wide association study of chemotherapy-induced alopecia in breast cancer patients., Breast cancer research : BCR, Chung, Suyoun S and 6 more authors.
  • 50. [Cystathionine γ-lyase]., Postepy higieny i medycyny doswiadczalnej (Online), Jurkowska, Halina H, Kaczor-Kamińska, Marta M, Bronowicka-Adamska, Patrycja P and Wróbel, Maria M.
  • 51. Decreased cystathionine-γ-lyase (CSE) activity in livers of type 1 diabetic rats and peripheral blood mononuclear cells (PBMC) of type 1 diabetic patients., The Journal of biological chemistry, Manna, Prasenjit P, Gungor, Neslihan N, McVie, Robert R and Jain, Sushil K SK.
  • 52. Hydrogen sulfide (H2S)/cystathionine γ-lyase (CSE) pathway contributes to the proliferation of hepatoma cells., Mutation research, Pan, Yan Y and 5 more authors.
  • 53. The cystathionine γ-lyase/hydrogen sulfide system maintains cellular glutathione status., The Biochemical journal, Lee, Zheng-Wei ZW, Low, Yi-Lian YL, Huang, Shufen S, Wang, Tianxiao T and Deng, Lih-Wen LW.
  • 54. The binding site for the transcription factor, NF-κB, on the cystathionine γ-lyase promoter is critical for LPS-induced cystathionine γ-lyase expression., International journal of molecular medicine, Wang, Maoxian M, Guo, Zhanyun Z and Wang, Shilong S.
  • 55. Regulation of cystathionine gamma-lyase/H₂S system and its pathological implication., Frontiers in bioscience (Landmark edition), Zhao, Kexin K, Li, Hongzhu H, Li, Shuangshuang S and Yang, Guangdong G.
  • 56. Dysregulation of hydrogen sulphide metabolism impairs oviductal transport of embryos., Nature communications, Ning, Nannan N and 5 more authors.
  • 57. Wnt/β-catenin signaling induces the transcription of cystathionine-γ-lyase, a stimulator of tumor in colon cancer., Cellular signalling, Fan, Kun K and 7 more authors.
  • 58. miRNA-30 family inhibition protects against cardiac ischemic injury by regulating cystathionine-γ-lyase expression., Antioxidants & redox signaling, Shen, Yaqi Y and 7 more authors.
  • 59. Role of the cystathionine γ lyase/hydrogen sulfide pathway in human melanoma progression., Pigment cell & melanoma research, Panza, Elisabetta E and 11 more authors.
  • 60. A proteome-scale map of the human interactome network., Cell, Rolland, Thomas T and 69 more authors.
  • 61. Neurodegeneration in Huntington's disease involves loss of cystathionine γ-lyase., Cell cycle (Georgetown, Tex.), Paul, Bindu D BD and Snyder, Solomon H SH.
  • 62. The importance of MTHFR, MTR, MTRR and CSE expression levels in Caucasian women with preeclampsia., European journal of obstetrics, gynecology, and reproductive biology, Seremak-Mrozikiewicz, Agnieszka A and 6 more authors.
  • 63. The importance of rs1021737 and rs482843 polymorphisms of cystathionine gamma-lyase in the etiology of preeclampsia in the Caucasian population., Ginekologia polska, Mrozikiewicz, Przemysław M PM and 8 more authors.
  • 64. Cystathionine γ-lyase, a H2S-generating enzyme, is a GPBAR1-regulated gene and contributes to vasodilation caused by secondary bile acids., American journal of physiology. Heart and circulatory physiology, Renga, Barbara B and 9 more authors.
  • 65. Correlation between the cystathionine-γ-lyase (CES) and the severity of peptic ulcer disease., African health sciences, Chen, Xiong X, Wan, Ying-Chun YC, Guo, Tao T, Xu, Can-Xia CX and Wang, Fen F.
  • 66. MPST but not CSE is the primary regulator of hydrogen sulfide production and function in the coronary artery., American journal of physiology. Heart and circulatory physiology, Kuo, Maggie M MM and 10 more authors.
  • 67. Transcriptional Regulation of Cystathionine-γ-Lyase in Endothelial Cells by NADPH Oxidase 4-Dependent Signaling., The Journal of biological chemistry, Mistry, Rajesh K RK and 8 more authors.
  • 68. LPS Up-Regulates Cystathionine γ -Lyase Gene Expression in Primary Human Macrophages via NF-κB/ERK Pathway., Inflammation & allergy drug targets, Badiei, Alireza A, Gieseg, Steven S, Davies, Sian S, Izani Othman, Mohd M and Bhatia, Madhav M.
  • 69. Radiation Exposure Promotes Hepatocarcinoma Cell Invasion through Epithelial Mesenchymal Transition Mediated by H2S/CSE Pathway., Radiation research, Pan, Yan Y, Zhou, Cuiping C, Yuan, Dexiao D, Zhang, Jianghong J and Shao, Chunlin C.
  • 70. Cystathionine γ-lyase(CSE)/hydrogen sulfide system is regulated by miR-216a and influences cholesterol efflux in macrophages via the PI3K/AKT/ABCA1 pathway., Biochemical and biophysical research communications, Gong, Duo D and 15 more authors.
  • 71. MicroRNA-186 promotes macrophage lipid accumulation and secretion of pro-inflammatory cytokines by targeting cystathionine γ-lyase in THP-1 macrophages., Atherosclerosis, Yao, Yan Y and 9 more authors.
  • 72. Cystathionine γ-lyase is expressed in human atherosclerotic plaque microvessels and is involved in micro-angiogenesis., Scientific reports, van den Born, J C JC and 5 more authors.
  • 73. Dichotomous effects of isomeric secondary amines containing an aromatic nitrile and nitro group on human aortic smooth muscle cells via inhibition of cystathionine-γ-lyase., Biochimie, Ji, Yajing Y and 6 more authors.
  • 74. Distinctive expression pattern of cystathionine-β-synthase and cystathionine-γ-lyase identifies mesenchymal stromal cells transition to mineralizing osteoblasts., Journal of cellular physiology, Gambari, Laura L and 6 more authors.
  • 75. Age-Dependent Allergic Asthma Development and Cystathionine Gamma-Lyase Deficiency., Antioxidants & redox signaling, Wang, Peipei P and 6 more authors.
  • 76. Augmented H2S production via cystathionine-beta-synthase upregulation plays a role in pregnancy-associated uterine vasodilation., Biology of reproduction, Sheibani, Lili L and 7 more authors.
  • 77. Total sulfane sulfur bioavailability reflects ethnic and gender disparities in cardiovascular disease., Redox biology, Rajpal, Saurabh S and 12 more authors.
  • 78. Oligo-capping: a simple method to replace the cap structure of eukaryotic mRNAs with oligoribonucleotides., Gene, Maruyama, K K and Sugano, S S.

Application Protocols

Item-specific facts (from Product Data)

• No tested applications are provided for this item.

General protocols for small-molecule screening (not specific to this item)

• Stock solution preparation:
  • Weigh accurately under low humidity if hygroscopicity is suspected.
  • Prepare a concentrated DMSO stock (e.g., 10–50 mM). Vortex and, if necessary, sonicate briefly. Record exact concentration by gravimetry or quantitative NMR where precision is required.
• Plate handling:
  • Dispense using acoustic or pin tools to minimize DMSO carryover.
  • Seal plates to limit evaporation; equilibrate to assay temperature before use.
• Assay execution:
  • Maintain constant final DMSO across all wells (typical 0.1–1% v/v).
  • Include positive/negative controls and, when appropriate, a counterscreen to detect assay interference.
• Data quality:
  • Track Z′ factor, include duplicates/triplicates, and confirm hits by independent resupply.
• Analytical confirmation:
  • Verify identity/purity of working stocks by LC-MS before critical studies.

These are general recommendations; adapt to your assay format and institutional SOPs.

Biological Roles

Item-specific facts (from Product Data)

• No biological role or target information is provided for this item.

General notes (not specific to this item)

• As a Moligand™ library member, this compound is intended for research screening. Any biological role (e.g., pathway modulation, target engagement) must be established experimentally for the specific target and system of interest.
• Prior to mechanistic claims, confirm activity in orthogonal assays, determine basic ADME/physicochemical properties (solubility, stability, permeability), and verify absence of assay interference (fluorescence, redox cycling, aggregation).

Research use only

• Not for diagnostic, clinical, or therapeutic use. No pharmacological or clinical claims are made for this item.

Buffer Applications

Not typically applicable

• This product is a discrete small molecule rather than a buffering agent. No defined buffering capacity or pKa set is provided for this item.

Practical guidance (general)

• When deploying in biochemical assays, select buffers compatible with the assay target (e.g., HEPES, Tris, PBS) and with the compound’s solubility/stability profile. Maintain constant ionic strength and pH to reduce variability.
• Keep final organic co-solvent levels (e.g., DMSO) as low as practical and consistent across controls and treated wells.

Item-specific data such as pKa, buffer compatibility, or solubility profiles are not specified for this item; refer to CoA/Spec Sheet or determine empirically.

Green Alternatives

Context

• This product is a screening compound, not a bulk solvent or reagent. “Green” considerations therefore focus on solvent choice, miniaturization, and waste minimization in screening and analytics.

Greener practices for handling small-molecule libraries (general guidance)

• Prefer aqueous assay buffers and minimize DMSO to the lowest effective concentration (often ≤0.1–0.5% v/v).
• Miniaturize assay volumes (e.g., 384/1536-well formats) to reduce chemical and plastic waste.
• Use high-boiling, low-toxicity mobile phases for prep/analytical separations when feasible; consider ethanol/water systems for UV detection where compatible.
• Implement plate sealing, controlled humidity, and inert headspace to extend stock longevity and reduce compound wastage.

Illustrative comparison of common co-solvents (general; not item-specific)

• DMSO: excellent solvency; moderate environmental/health concern; persistent in wastewater.
• Ethanol: renewable and lower toxicity; solvency limitations for hydrophobic chemotypes.
• 2-MeTHF (for synthesis/purification contexts): bio-based, greener than THF; applicability depends on structure.

Always evaluate alternative solvents against assay performance, compound stability, and regulatory constraints.

Pharmaceutical Uses

Not applicable for regulated formulation claims

• No pharmacopeial status, excipient role, or manufacturing specification is provided for this item. It is supplied strictly for research use (screening/ligand discovery) and is not intended for clinical or diagnostic applications.

General considerations for research compounds

• If used as a starting point in preformulation studies, determine solid form (polymorph/solvate), stability (thermal, oxidative, photolytic), and solubility across pH to guide salt selection or enabling formulations—these are not provided for this item and must be established experimentally.
• Follow institutional and regulatory guidance for handling non-GMP research materials outside of clinical settings.

Physical Properties

Item-specific facts (from Product Data)

• Appearance: Not specified for this item; refer to CoA/Spec Sheet.

Not specified for this item; refer to CoA/Spec Sheet (do not treat as specifications)

• Melting point, boiling point, density, refractive index, UV–Vis cutoff, logP/logD, pKa, aqueous solubility.

General/literature guidance for small-molecule library members (not specific to this item)

• Many screening compounds are supplied as solids with moderate lipophilicity (typical cLogP 1–4, literature) and limited aqueous solubility, thus commonly prepared as DMSO stocks (e.g., 10–50 mM) before aqueous dilution.
• Hygroscopicity and polymorphism can affect apparent melting behavior and solubility; verify against the specific batch CoA and perform a small solubility test in intended assay media.
• If UV detection is planned (HPLC/UPLC), determine the compound’s UV spectrum experimentally; drug-like chromophores often absorb between 200–350 nm (literature), but the exact λmax is structure-dependent.

Quality and Grades

Item-specific facts (from Product Data)

• Grade/Purity: Moligand™

What Moligand™ implies (general description; not a spec)

• Moligand™ denotes a screening/ligand-discovery grade small molecule appropriate for HTS, hit validation, and SAR exploration. Emphasis is typically placed on identity confirmation and suitability for biochemical/cellular assays.

Typical quality attributes for small-molecule screening items (verify on CoA for this item)

• Identity: confirmed by NMR/LC-MS (methods and acceptance criteria vary by supplier; check CoA).
• Purity: often reported by HPLC/UPLC area %; exact minimum not specified for this item; refer to CoA/Spec Sheet.
• Counter-ions/solvates: documented if applicable; refer to CoA.
• Residual solvents, water, metal content, and stabilizers: Not specified for this item; refer to CoA/Spec Sheet.

Practical considerations

• For quantitative biology or medicinal chemistry, confirm batch-specific purity and identity before SAR decisions.
• If analytical detection is UV-based, ensure low-UV baseline from solvents and verify chromatographic homogeneity using your in-house method.

Reaction and Applications

Item-specific facts (from Product Data)

• Manufacturer Applications: Not specified for this item.

General applications for Moligand™ small-molecule library members (not specific to this item)

• High-throughput screening (HTS) and hit-finding across biochemical, biophysical (e.g., thermal shift, MST, SPR), and cell-based assays.
• Hit expansion and SAR: resupply to confirm activity, generate dose–response curves, and triage via orthogonal assays to rule out assay interference.
• Chemical biology: preliminary probe exploration, phenotypic screening, and pathway interrogation, subject to follow-up validation.

Practical tips

• Implement PAINS/REOS and aggregator filters computationally; verify experimentally via detergent tests or dynamic light scattering where appropriate.
• Confirm purity and identity on receipt (LC-MS/HPLC). Impurities can confound potency and mechanism interpretations.
• Prepare and store DMSO stocks in low-bind vials under inert headspace when possible; minimize freeze–thaw.
• For mechanistic assays, include counterscreens (redox activity, fluorescence interference, metal chelation) to identify false positives.

Note: No reaction chemistry or named-reaction usage is claimed for this specific item due to absent structural information.

Reaction Conditions

Not applicable to this item

• No reaction chemistry is specified for AC-178,335; it is not sold as a reagent for named reactions. Therefore, typical temperatures, catalysts, or yields are not provided.

General guidance (if used in assay-development workflows)

• For biochemical/cellular assays, typical working concentrations range from 0.1–30 µM after dilution from a concentrated DMSO stock; exact conditions are assay- and target-dependent and must be optimized empirically.
• Stability checks (general): verify compound integrity in assay buffer over the incubation period (e.g., by LC-MS at t=0 and t=end).

Safety and Handling

Item-specific facts (from Product Data)

• Storage conditions: Room temperature.
• Hazard information (GHS signal word, hazard statements, pictograms, classification): Not specified for this item; refer to SDS.

General safety guidance (not specific to this item; follow your institutional EHS policies)

• Personal protective equipment: lab coat, safety glasses, and appropriate chemically resistant gloves. Work in a fume hood to avoid inhalation of dusts or vapors.
• Avoid ingestion, inhalation, and skin/eye contact. Wash thoroughly after handling. Do not pipette by mouth.
• Incompatibilities and stability are structure-dependent; until confirmed, segregate from strong oxidizers, strong acids/bases, and ignition sources. Keep container tightly closed, protected from moisture and direct sunlight.
• First aid (overview; defer to SDS): if on skin/eyes, rinse with water for ≥15 minutes; if inhaled, move to fresh air; if ingested, seek medical attention. Provide SDS to responders.
• Spill response: contain, avoid dust generation, collect with inert absorbent, and dispose via approved chemical waste routes.
• Waste disposal: treat as organic chemical waste; comply with local regulations and your institutional waste program.

Always consult the product-specific SDS for authoritative hazard classification and response measures.

Solvent Selection

Item-specific facts (from Product Data)

• No solvent recommendations provided for this item; refer to CoA/Spec Sheet.

General guidance for small-molecule library compounds (literature/best practice)

• Stock preparation: DMSO is the standard solvent for preparing concentrated stocks (e.g., 10–50 mM). If insoluble, consider DMF or mixtures (DMSO:H2O or DMSO:buffer) and confirm assay compatibility.
• Aqueous use: After preparing a DMSO stock, dilute into assay buffer (e.g., PBS, HEPES, Tris) while keeping final DMSO typically ≤0.1–1% v/v to minimize biological interference.
• Solubility screening strategy:
  • Start with DMSO; if limited, warm gently (≤40 °C) and sonicate briefly.
  • Test co-solvents (MeOH, acetonitrile) for analytical work; for biology, maintain acceptable cosolvent levels.
  • Consider salt formation (if ionizable) to enhance aqueous solubility; requires structural knowledge and pKa data.
• Analytical compatibility: For LC-MS, acetonitrile/water with 0.1% formic acid (ESI+) or 5–10 mM ammonium acetate (ESI−) are common; adapt to the compound’s ionization behavior.

Comparison (general)

• DMSO: highest solvating power, excellent stability; potential biological effects ≥1–2%.
• DMF: strong solvent; greater toxicity concerns; avoid in live-cell assays when possible.
• MeOH/EtOH: useful for analytics; limited for cell assays beyond low percentages.

Storage and Reconstitution

Item-specific facts (from Product Data)

• Storage conditions: Room temperature.
• Shipped in: Not specified for this item; refer to CoA/Spec Sheet.

General guidance (not specific to this item)

• Primary storage: keep tightly closed in a desiccated environment, protected from light. Use inert headspace (e.g., argon/nitrogen) for air/moisture-sensitive chemotypes.
• DMSO stock solutions: prepare aliquots (e.g., 10–50 mM) and store at −20 to −80 °C to minimize degradation and freeze–thaw cycles. Thaw at room temperature, mix thoroughly, and visually inspect for precipitates before use.
• Aqueous working solutions: prepare fresh daily unless stability is established. Filter (0.22 µm) if compatible and necessary for assays.
• Stability: oxidative, hydrolytic, and photolytic susceptibilities are structure-dependent. Establish stability-indicating LC methods to monitor over time.

Note: In the absence of item-specific stability data, defer to the product CoA/SDS and perform small-scale pilot tests to confirm handling and storage conditions in your laboratory context.

Structure and Identity

Item-specific facts (from Product Data)

• Product name: AC-178,335 (SKU: rp173361)
• CAS: 212966-15-9
• PubChem CID: 9832890
• Grade: Moligand™ (small-molecule library quality)
• Molecular formula: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.
• SMILES: Not specified for this item; refer to CoA/Spec Sheet.
• InChIKey: Not specified for this item; refer to CoA/Spec Sheet.

General chemistry notes (no structural claim for this item)

• This product is categorized under “small molecules and compound libraries,” suggesting a discrete, drug-like organic molecule intended for screening and ligand-discovery workflows.
• Without a provided structure, functional groups, ring systems, and stereochemistry cannot be summarized for this specific item. Consult the CoA/SDS or supplier structure file (SDF/MOL) for definitive identity and descriptor fields (SMILES/InChI).

Synthetic Utility

Limited applicability

• Without structural information, this item is not presented as a synthetic reagent or building block. Its primary role is as a screening compound within a small-molecule library.

General notes (not item-specific)

• If structural details become available, assess functional handles (halides, boronates, amines, acids) for potential analogue synthesis to support SAR. Typical transformations could include amide couplings, cross-couplings (Suzuki, Buchwald–Hartwig), or heterocycle elaborations as dictated by the scaffold.
• For procurement strategies, confirm availability of close analogues or intermediates to enable rapid hypothesis testing in medicinal chemistry.

Target Specificity

Item-specific facts (from Product Data)

• No target, pathway, or selectivity profile is provided for this item.

General guidance (not specific to this item)

• Establish target specificity through a combination of primary assays, orthogonal biophysical methods (SPR, ITC, DSF), selectivity panels, and counter-screens for common artifacts (redox activity, metal chelation, aggregation, fluorescence interference).
• Report potency as IC50/EC50/Kd with confidence intervals, and confirm mechanism (competitive/noncompetitive, covalent/reversible) where applicable.

Research use only

• No claims are made regarding biological targets for AC-178,335.

Domande frequenti

What documentation is provided?

Available product documentation, including Certificates of Analysis (COA), Safety Data Sheets (SDS), and specification sheets, is shown in the product document area. Document availability and access follow the current site policy.

What is Moligand??

Moligand? is one of Aladdin Scientific's premium product lines, formulated for high-purity applications across multiple workflows. Compared to standard grades in the same workflow, Moligand? products typically offer tighter specifications, more rigorous QC, and stronger lot-to-lot consistency.

How should this product be stored?

Store at room temperature.

What are the CAS number, molecular formula and molecular weight?

The CAS Number is 212966-15-9.